IL212922A0
Antibody formulation
Abstract
This record has no abstract on file.
Term
No projected expiry on record.
- Priority
- Filed
- Published
- Today
78 members in 32 offices
Priority claims2
| Document | Office | Kind | Date |
|---|---|---|---|
| 08170884 | European Patent Office (EPO) | A | |
| 2009066675 | European Patent Office (EPO) | W |
Members78
| Document | Office | Kind | |
|---|---|---|---|
| EP2196476A1 | European Patent Office (EPO) | A1 | |
| CA2745938A1 | Canada | A1 | |
| WO2010066762A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU2009324371A1 | Australia | A1 | |
| MX2011006242A | Mexico | A | |
| IL212922A0This record | Israel | A0 | |
| IL212922D0 | Israel | D0 | |
| ECSP11011192A | Ecuador | A | |
| US2011236398A1 | United States of America | A1 | |
| EP2376533A1 | European Patent Office (EPO) | A1 | |
| CN102245639A | China | A | |
| CO6361952A2 | Colombia | A2 | |
| ZA201103362B | South Africa | B | |
| KR20120009421A | Republic of Korea | A | |
| MA33023B1 | Morocco | B1 | |
| CL2011001406A1 | Chile | A1 | |
| PE20120342A1 | Peru | A1 | |
| JP2012511540A | Japan | A | |
| HK1159130A | Hong Kong, China | A | |
| HK1159130A1 | Hong Kong, China | A1 | |
| US2012315285A1 | United States of America | A1 | |
| TN2011000229A1 | Tunisia | A1 | |
| NZ592918A | New Zealand | A | |
| RU2011127913A | Russian Federation | A | |
| AU2009324371B2 | Australia | B2 | |
| US8623367B2 | United States of America | B2 | |
| CN102245639B | China | B | |
| CN104399076A | China | A | |
| RU2563179C2 | Russian Federation | C2 | |
| JP2015231997A | Japan | A | |
| EP2376533B1 | European Patent Office (EPO) | B1 | |
| DK2376533T3 | Denmark | T3 | |
| PT2376533T | Portugal | T | |
| MY157772A | Malaysia | A | |
| SI2376533T1 | Slovenia | T1 | |
| HRP20160754T1 | Croatia | T1 | |
| ES2579835T3 | Spain | T3 | |
| SMT201600222B | San Marino | B | |
| EP3072906A1 | European Patent Office (EPO) | A1 | |
| PL2376533T3 | Poland | T3 | |
| HUE028408T2 | Hungary | T2 | |
| KR20170044211A | Republic of Korea | A | |
| CY1117735T1 | Cyprus | T1 | |
| JP6143416B2 | Japan | B2 | |
| KR101762966B1 | Republic of Korea | B1 | |
| CA2745938C | Canada | C | |
| MY166050A | Malaysia | A | |
| JP2018168158A | Japan | A | |
| BRPI0922730A2 | Brazil | A2 | |
| RU2015132431A | Russian Federation | A | |
| RU2015132431A3 | Russian Federation | A3 | |
| IL212922A | Israel | A | |
| IL212922B | Israel | B | |
| IL264316A | Israel | A | |
| IL264316D0 | Israel | D0 | |
| IL276622A | Israel | A | |
| IL276622D0 | Israel | D0 | |
| US2020384108A1 | United States of America | A1 | |
| JP2020203889A | Japan | A | |
| EP3792282A1 | European Patent Office (EPO) | A1 | |
| RU2745601C2 | Russian Federation | C2 | |
| EP3072906B1 | European Patent Office (EPO) | B1 | |
| CN104399076B | China | B | |
| DK3072906T3 | Denmark | T3 | |
| PT3072906T | Portugal | T | |
| LT3072906T | Lithuania | T | |
| PL3072906T3 | Poland | T3 | |
| SI3072906T1 | Slovenia | T1 | |
| HUE056626T2 | Hungary | T2 | |
| HRP20211899T1 | Croatia | T1 | |
| ES2900624T3 | Spain | T3 | |
| CN114225022A | China | A | |
| CY1124844T1 | Cyprus | T1 | |
| JP7286595B2 | Japan | B2 | |
| JP2023109938A | Japan | A | |
| IL264316B1 | Israel | B1 | |
| IL264316B2 | Israel | B2 | |
| JP2026021446A | Japan | A |
3 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Patent renewedKB | KB | |
| Patent renewedKB | KB | |
| Patent grantedGrantedFF | FF |
Numbers
- Application
- 21292211
Titles
- English
- ANTIBODY FORMULATION
Classification
- CPC, 10
- A61K39/39591
- A61K9/08
- A61K9/0019
- A61K9/19
- C07K16/245
- A61K47/183
- A61P37/00
- A61K47/36
- A61K39/395
- A61P19/02